Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01E: Pembrolizumab + Sacituzumab Tirumotecan in Resectable NSCLC
NCT06788912Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Primary completion
- Feb 2032
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Mar 2025; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06788912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788912.